Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6471MR)

This product GTTS-WQ6471MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6471MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1758MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ10657MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ9802MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ5579MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ2146MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ10493MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ77MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15478MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW